Erasca Inc. (NASDAQ:ERAS) is one of the 10 Stocks Dominating Today’s Market Action.
Erasca rallied for a second day on Thursday, jumping 13.04 percent to close at $15.26 apiece on strong investor optimism, backed by earlier optimistic coverage from several analysts.
Year-to-date, the company has already seen its stock price soar by 310 percent, making it one of the top-performing stocks this year.
Investors are also positioning portfolios ahead of initial data from clinical trials to test the efficacy of its treatment candidate, ERAS-0015, in patients with RAS-mutant solid tumors in the US and China.
Photo by RDNE on Pexels
In January this year, ERAS-0015 showed early promising results in one of Erasca Inc.’s (NASDAQ:ERAS) clinical studies, particularly during dose escalations.
According to the company, it saw two confirmed partial responses and one unconfirmed partial response during the clinical study of its pan-RAS molecular glue degrader ERAS-0015.
In addition, more unconfirmed responses were observed in patients taking 8 mg doses, with consistent, linear pharmacokinetics across all dose levels evaluated and no evidence of exposure plateau so far.
While we acknowledge the potential of ERAS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
